NR 566: Advanced Pharmacology
Midterm & Final Exam Study Guide
Chamberlain University | 2026
Comprehensive Review with Practice Questions &
Rationales
About This Study Guide
This guide is designed to help you master the advanced pharmacology concepts
tested on the NR 566 Midterm and Final Examinations. It is organized by key content
areas and includes:
• Systematic Content Review: Key concepts organized by body system and drug
class
• Practice Questions: Over 200 questions with expert rationales
• Clinical Pearls: High-yield information for exam success
• Drug Comparison Tables: Quick reference for commonly tested medications
Table of Contents
1. Pharmacokinetics & Pharmacodynamics
2. Pharmacogenomics & Special Populations
3. Infectious Disease Pharmacology
4. Cardiovascular Pharmacology
5. Endocrine & Metabolic Pharmacology
6. Neurologic & Psychiatric Pharmacology
7. Pain Management & Controlled Substances
8. Respiratory & GI Pharmacology
,9. Hematology & Immunology
10. Practice Examination – 100 Questions with Rationales
Section 1: Pharmacokinetics & Pharmacodynamics
Key Concepts
Concept Definition Clinical Application
Movement of drug from
Absorption Affected by route, gastric pH, bloo
administration site into bloodstream
Movement of drug from blood to Affected by protein binding, lipoph
Distribution
tissues blood flow
CYP450 system; inducers increase
Biotransformation of drugs (primarily
Metabolism metabolism; inhibitors decrease
liver)
metabolism
Elimination of drugs from body Renal impairment requires dose
Excretion
(primarily kidneys) adjustment
Time for drug concentration to
Half-life (t½) Steady state reached in 4-5 half-liv
decrease by 50%
Volume of Theoretical volume of fluid High Vd = extensive tissue distribu
Distribution (Vd) containing total drug dose (lipophilic drugs)
Fraction of administered drug that Oral drugs affected by first-pass
Bioavailability
reaches systemic circulation metabolism
,Drug-Receptor Interactions
Term Definition
Agonist Activates receptor to produce a response
Antagonist Blocks receptor, preventing response
Reversibly binds to same site as agonist; effect overcome by increasin
Competitive Antagonist
agonist
Non-competitive
Irreversibly binds or binds to allosteric site; reduces maximal response
Antagonist
Partial Agonist Produces submaximal response even at full receptor occupancy
Potency Amount of drug needed to produce a given effect (EC50)
Efficacy Maximal response a drug can produce
CYP450 Enzyme System
Common
Enzyme Common Substrates Common Inhibitors
Inducers
Amlodipine, statins, Ketoconazole, Rifampin,
CYP3A4 benzodiazepines, clarithromycin, carbamazepine, St.
warfarin grapefruit juice John's wort
Fluoxetine,
CYP2D6 Codeine, paroxetine, None significant
antidepressants, bupropion
, Common
Enzyme Common Substrates Common Inhibitors
Inducers
antipsychotics,
metoprolol
Amiodarone,
Warfarin, phenytoin,
CYP2C9 fluconazole, TMP- Rifampin
NSAIDs
SMX
Clopidogrel, Omeprazole,
CYP2C19 Rifampin
omeprazole, diazepam fluconazole
Practice Questions
1. A 75-year-old patient with heart failure and hypoalbuminemia is prescribed a
highly protein-bound drug. The NP anticipates which pharmacokinetic change?
A. Decreased volume of distribution
B. Increased free drug concentration and risk of toxicity
C. Decreased drug half-life
D. Increased first-pass metabolism
Answer: B
Expert Rationale: Hypoalbuminemia reduces protein binding sites, increasing the
fraction of free (active) drug. Combined with age-related renal decline, this
significantly increases toxicity risk.
2. A patient is a CYP2D6 poor metabolizer. Which medication would have
reduced efficacy due to impaired activation?
A. Omeprazole
B. Codeine
C. Diazepam
D. Propranolol
Answer: B
Expert Rationale: Codeine is a prodrug requiring CYP2D6-mediated conversion
to its active metabolite, morphine. Poor metabolizers have reduced conversion,
leading to inadequate analgesia.
Midterm & Final Exam Study Guide
Chamberlain University | 2026
Comprehensive Review with Practice Questions &
Rationales
About This Study Guide
This guide is designed to help you master the advanced pharmacology concepts
tested on the NR 566 Midterm and Final Examinations. It is organized by key content
areas and includes:
• Systematic Content Review: Key concepts organized by body system and drug
class
• Practice Questions: Over 200 questions with expert rationales
• Clinical Pearls: High-yield information for exam success
• Drug Comparison Tables: Quick reference for commonly tested medications
Table of Contents
1. Pharmacokinetics & Pharmacodynamics
2. Pharmacogenomics & Special Populations
3. Infectious Disease Pharmacology
4. Cardiovascular Pharmacology
5. Endocrine & Metabolic Pharmacology
6. Neurologic & Psychiatric Pharmacology
7. Pain Management & Controlled Substances
8. Respiratory & GI Pharmacology
,9. Hematology & Immunology
10. Practice Examination – 100 Questions with Rationales
Section 1: Pharmacokinetics & Pharmacodynamics
Key Concepts
Concept Definition Clinical Application
Movement of drug from
Absorption Affected by route, gastric pH, bloo
administration site into bloodstream
Movement of drug from blood to Affected by protein binding, lipoph
Distribution
tissues blood flow
CYP450 system; inducers increase
Biotransformation of drugs (primarily
Metabolism metabolism; inhibitors decrease
liver)
metabolism
Elimination of drugs from body Renal impairment requires dose
Excretion
(primarily kidneys) adjustment
Time for drug concentration to
Half-life (t½) Steady state reached in 4-5 half-liv
decrease by 50%
Volume of Theoretical volume of fluid High Vd = extensive tissue distribu
Distribution (Vd) containing total drug dose (lipophilic drugs)
Fraction of administered drug that Oral drugs affected by first-pass
Bioavailability
reaches systemic circulation metabolism
,Drug-Receptor Interactions
Term Definition
Agonist Activates receptor to produce a response
Antagonist Blocks receptor, preventing response
Reversibly binds to same site as agonist; effect overcome by increasin
Competitive Antagonist
agonist
Non-competitive
Irreversibly binds or binds to allosteric site; reduces maximal response
Antagonist
Partial Agonist Produces submaximal response even at full receptor occupancy
Potency Amount of drug needed to produce a given effect (EC50)
Efficacy Maximal response a drug can produce
CYP450 Enzyme System
Common
Enzyme Common Substrates Common Inhibitors
Inducers
Amlodipine, statins, Ketoconazole, Rifampin,
CYP3A4 benzodiazepines, clarithromycin, carbamazepine, St.
warfarin grapefruit juice John's wort
Fluoxetine,
CYP2D6 Codeine, paroxetine, None significant
antidepressants, bupropion
, Common
Enzyme Common Substrates Common Inhibitors
Inducers
antipsychotics,
metoprolol
Amiodarone,
Warfarin, phenytoin,
CYP2C9 fluconazole, TMP- Rifampin
NSAIDs
SMX
Clopidogrel, Omeprazole,
CYP2C19 Rifampin
omeprazole, diazepam fluconazole
Practice Questions
1. A 75-year-old patient with heart failure and hypoalbuminemia is prescribed a
highly protein-bound drug. The NP anticipates which pharmacokinetic change?
A. Decreased volume of distribution
B. Increased free drug concentration and risk of toxicity
C. Decreased drug half-life
D. Increased first-pass metabolism
Answer: B
Expert Rationale: Hypoalbuminemia reduces protein binding sites, increasing the
fraction of free (active) drug. Combined with age-related renal decline, this
significantly increases toxicity risk.
2. A patient is a CYP2D6 poor metabolizer. Which medication would have
reduced efficacy due to impaired activation?
A. Omeprazole
B. Codeine
C. Diazepam
D. Propranolol
Answer: B
Expert Rationale: Codeine is a prodrug requiring CYP2D6-mediated conversion
to its active metabolite, morphine. Poor metabolizers have reduced conversion,
leading to inadequate analgesia.
